Which cancer type is most commonly associated with CAR T-cell therapy?

Which cancer type is most commonly associated with CAR T-cell therapy?

• A. Breast cancer
• B. Prostate cancer
• C. Acute lymphoblastic leukemia (ALL)
• D. Colorectal cancer

Answer: (C)

CAR T-cell therapy has become particularly prominent in the treatment of hematologic malignancies, with acute lymphoblastic leukemia (ALL) being one of the most successfully targeted cancers. This innovative form of immunotherapy involves genetically engineering a patient's T-cells to express chimeric antigen receptors (CARs) that specifically recognize and attack cancer cells. In the case of ALL, particularly in pediatric populations, substantial clinical trials have demonstrated that CAR T-cell therapy can lead to significant remission rates and even long-term survival in patients who have not responded to conventional treatments. The therapy targets the CD19 protein, which is commonly found on the surface of B-cell leukemia and lymphoma cells, thus allowing the engineered T-cells to identify and eliminate these malignant cells effectively. While CAR T-cell therapy is being investigated and applied in other cancers, such as certain types of lymphomas and multiple myeloma, the overwhelming efficacy and established use in ALL make it the cancer type most closely associated with this form of therapy.

CAR T-cell therapy has become particularly prominent in the treatment of hematologic malignancies, with acute lymphoblastic leukemia (ALL) being one of the most successfully targeted cancers. This innovative form of immunotherapy involves genetically engineering a patient's T-cells to express chimeric antigen receptors (CARs) that specifically recognize and attack cancer cells.

In the case of ALL, particularly in pediatric populations, substantial clinical trials have demonstrated that CAR T-cell therapy can lead to significant remission rates and even long-term survival in patients who have not responded to conventional treatments. The therapy targets the CD19 protein, which is commonly found on the surface of B-cell leukemia and lymphoma cells, thus allowing the engineered T-cells to identify and eliminate these malignant cells effectively.

While CAR T-cell therapy is being investigated and applied in other cancers, such as certain types of lymphomas and multiple myeloma, the overwhelming efficacy and established use in ALL make it the cancer type most closely associated with this form of therapy.